A credible current or recent warfarin history can pause one treatment decision—IV thrombolysis—until the INR is available. It should not put the entire stroke response on hold.
Take this illustrative stroke-alert scenario: a patient with a disabling focal deficit arrives within a potential IV-thrombolysis window. Noncontrast CT excludes hemorrhage. Medication reconciliation indicates a warfarin prescription, but recent use and last dose are uncertain. The initial blood pressure is 192/108, and CTA is being arranged. The practical question is not just “Can I give a clot-buster now?” It is “Which parts of reperfusion care must wait for the INR, and which should keep moving?”
The INR is a gate for IV thrombolysis—not a verdict on the whole case
When current or recent warfarin exposure is credible, hold IV thrombolysis until the INR is known. The 2026 AHA/ASA threshold is that IV thrombolysis should not be given when INR is greater than 1.7. An INR of 1.7 or less removes this particular barrier; it does not establish eligibility by itself. Confirm the remaining clinical and imaging criteria, including whether the deficit is disabling and whether blood pressure can be brought below the treatment threshold.
Order a stat INR and clarify the drug and last dose at the same time. A medication list can indicate that warfarin is prescribed, but does not establish whether the patient took it recently or what the current anticoagulant effect is. Conversely, uncertain adherence does not justify assuming warfarin has no effect before the INR returns.
The initial pressure in this example also matters: 192/108 is above the systolic threshold for IV thrombolysis. If the patient otherwise qualifies, lower blood pressure in a controlled way to below 185/110 mmHg before treatment. Do not chase a normal reading; if the threshold cannot be achieved and maintained, IV thrombolysis is not appropriate under the usual pathway.
| Decision or task | What to do while the INR is pending |
|---|---|
| IV thrombolysis | Hold until the INR is known when current or recent warfarin exposure is credible. If INR is ≤1.7 and other criteria are met, treatment can be considered. |
| Blood pressure | Treat in parallel if IV thrombolysis may be an option; the pre-treatment target is below 185/110 mmHg. |
| Medication history | Ask about the exact drug, last dose, missed doses, and indication; check available records or medication packaging. |
Keep the imaging and thrombectomy pathway moving
A medication-related pause in IV thrombolysis is not a reason to pause the stroke alert. Obtain noncontrast CT promptly to exclude hemorrhage. For a patient with a severe focal deficit and possible large-vessel occlusion, obtain CTA of the head and neck as early as the local workflow allows.
For patients otherwise eligible for IV thrombolysis within the standard 4.5-hour window, noncontrast CT is generally sufficient for the IV-thrombolysis imaging decision. Do not wait for CTA interpretation or additional perfusion imaging if doing so would delay treatment. Patients in extended or unknown-onset windows may need advanced imaging to establish eligibility.
If CTA identifies a potentially treatable large-vessel occlusion, contact the thrombectomy-capable team or arrange transfer without waiting to see whether IV thrombolysis improves the examination. If the patient is eligible for both treatments, the planned endovascular procedure is not, by itself, a reason to skip IV thrombolysis.
An occlusion on CTA triggers urgent EVT assessment; it does not guarantee that every patient proceeds to thrombectomy. The specialist team still considers the vessel and imaging findings, time course, clinical status, and relevant baseline function. Ask family about the patient’s usual mobility and independence while the imaging and consultation proceed—do not fill in an unknown baseline by assumption.
This separation is the key workflow habit: warfarin-related uncertainty may hold IV thrombolysis, but it does not settle whether an arterial occlusion is present or whether EVT is appropriate. Keep those decisions on parallel tracks.
“Oral anticoagulant” is not one laboratory problem
If the drug turns out to be warfarin, the INR is the relevant immediate test for this decision. If it is a direct oral anticoagulant (DOAC), do not apply the warfarin cutoff as if it measured that drug’s effect. Routine PT/INR testing may not reliably exclude clinically meaningful DOAC activity.
For recent DOAC exposure (within 48 hours), the 2026 AHA/ASA guideline describes the safety of IV thrombolysis as uncertain and calls for an individualized risk–benefit assessment. Relevant considerations include the timing of the last dose, renal function, stroke severity, EVT availability, reversal options, and availability of appropriate DOAC-specific assays. Involve the stroke team and follow the local testing pathway; a normal INR alone does not clear the patient for IV thrombolysis.
The safe exam answer is therefore not “all anticoagulants are the same” or “a normal coagulation panel means no drug effect.” Name the medicine, identify the assay that addresses it, and involve stroke expertise promptly.
Common traps
- Starting thrombolysis before the INR because the last dose is unknown. A credible current or recent warfarin history means the INR must be checked first.
- Treating INR ≤1.7 as automatic clearance. It removes one warfarin-related obstacle; the rest of the eligibility assessment still applies.
- Letting an IV-thrombolysis hold stop CTA or EVT evaluation. These are separate decisions, and a possible large-vessel occlusion needs prompt assessment.
- Using a normal INR to rule out DOAC activity. Standard INR testing does not reliably do that.
- Lowering blood pressure to normal. If IV thrombolysis is being considered, lower it carefully to the required threshold rather than overshooting.
Practical takeaways
- With credible current or recent warfarin exposure, wait for the INR before IV thrombolysis; INR >1.7 means do not give it.
- If INR is ≤1.7, assess all other treatment criteria before proceeding.
- Control elevated blood pressure in parallel; the pre-thrombolysis target is <185/110 mmHg.
- Continue CT/CTA, stroke-team activation, and EVT evaluation while the INR is pending.
- Identify the exact anticoagulant: warfarin and DOACs require different reasoning and testing.
